MCID: CMM004
MIFTS: 67

Common Variable Immunodeficiency malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Common Variable Immunodeficiency

About this section
Sources:
11Disease Ontology, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Common Variable Immunodeficiency:

Name: Common Variable Immunodeficiency 35 11 48 25 54 50 39 13 68
Cvid 11 48 24 25 54
Common Variable Immune Deficiency 48 24 25
Idiopathic Immunoglobulin Deficiency 48 54
Immunodeficiency, Common Variable 25 27
Acquired Hypogammaglobulinemia 11 68
Primary Hypogammaglobulinemia 48 54
Primary Antibody Deficiency 48 54
 
Common Variable Hypogamma-Globulinemia 48
Common Variable Hypogammaglobulinemia 25
Immunoglobulin Deficiency, Late-Onset 48
Combined Variable Immune Deficiency 24
Common Variable Agammaglobulinemia 11
Hypogamma-Globulinemia, Acquired 48
Sporadic Hypogammaglobulinemia 11
Acquired Agammaglobulinemia 11

Characteristics:

Orphanet epidemiological data:

54
common variable immunodeficiency:
Inheritance: Autosomal dominant,Autosomal recessive,Not applicable; Prevalence: 1-9/100000; Age of onset: All ages

Classifications:



External Ids:

Disease Ontology11 DOID:12177
ICD1030 D83, D83.9
ICD9CM32 279.06
MeSH39 D017074
SNOMED-CT62 191010004, 23238000
Orphanet54 ORPHA1572
MESH via Orphanet40 D017074
ICD10 via Orphanet31 D83.0, D83.9, D83.1 D83.2, D83.8, more
UMLS via Orphanet69 C0009447

Summaries for Common Variable Immunodeficiency

About this section
NIH Rare Diseases:48 Common variable immunodeficiency (CVID) is a group of disorders in which the immune system cannot make antibodies against agents that cause infection (such as bacteria). CVID is characterized by low levels of most or all of the immunoglobulin (Ig) classes. This causes affected people to get frequent infections, particularly in the sinuses, lungs, and digestive tract. Symptoms most commonly begin in early adulthood but have been found in children as young as age two. While in most cases the cause of CVID is unknown, it has been associated with changes (mutations) in at least 10 genes. About 10% of cases are due to mutations in the TNFRSF13B gene. Treatment for CVID includes Ig replacement therapy, which stops the cycle of recurrent infections. Last updated: 3/14/2016

MalaCards based summary: Common Variable Immunodeficiency, also known as cvid, is related to immunodeficiency, common variable, 1 and hemolytic anemia, and has symptoms including sinusitis, otitis media and thrombocytopenia. An important gene associated with Common Variable Immunodeficiency is TNFRSF13C (TNF Receptor Superfamily Member 13C), and among its related pathways are Interleukin-1 processing and Dendritic Cells Developmental Lineage Pathway. Affiliated tissues include b cells, lung and t cells, and related mouse phenotypes are digestive/alimentary and liver/biliary system.

Disease Ontology:11 A hypogammaglobulinemia that is results in insufficient production of antibodies needed to respond to exposure of pathogens and is characterized by low Ig levels with phenotypically normal B cells that can proliferate but do not develop into Ig-producing cells. Patients with common variable immunodeficiency have marked reduction in serum levels of both immunoglobulin G (IgG) and immunoglobulin A (IgA); about half of these patients also have reduced immunoglobulin M (IgM).

Genetics Home Reference:25 Common variable immune deficiency (CVID) is a disorder that impairs the immune system. People with CVID are highly susceptible to infection from foreign invaders such as bacteria, or more rarely, viruses and often develop recurrent infections, particularly in the lungs, sinuses, and ears. Pneumonia is common in people with CVID. Over time, recurrent infections can lead to chronic lung disease. Affected individuals may also experience infection or inflammation of the gastrointestinal tract, which can cause diarrhea and weight loss. Abnormal accumulation of immune cells causes enlarged lymph nodes (lymphadenopathy) or an enlarged spleen (splenomegaly) in some people with CVID. Immune cells can accumulate in other organs, forming small lumps called granulomas.

Wikipedia:71 Common variable immunodeficiency (CVID) is an immune disorder characterized by recurrent infections and... more...

Related Diseases for Common Variable Immunodeficiency

About this section

Diseases related to Common Variable Immunodeficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 294)
idRelated DiseaseScoreTop Affiliating Genes
1immunodeficiency, common variable, 132.7ICOS, NFKB2
2hemolytic anemia31.0CD19, CD40LG, CD79A, IL2
3rheumatoid arthritis30.6CD40LG, CD79A, IL2, IL4, SH2D1A, TNFSF13B
4hemolytic-uremic syndrome30.6CD40LG, CD79A
5systemic lupus erythematosus30.4CD40LG, CD79A, CR2, IL2, IL4, SH2D1A
6immunodeficiency, common variable, 1011.8
7cd19-related common variable immune deficiency11.2
8cr2-related common variable immune deficiency11.2
9icos-related common variable immune deficiency11.2
10tnfrsf13b-related common variable immune deficiency11.2
11tnfrsf13c-related common variable immune deficiency11.2
12autoimmune lymphoproliferative syndrome, type iii11.1
13familial cold autoinflammatory syndrome 311.1
14immunodeficiency-centromeric instability-facial anomalies syndrome 111.1
15cutaneous candidiasis10.9TNFRSF13B, TNFRSF13C, TNFSF13B
16calcific tendinitis10.9CD40LG, CD79A
17medullary sponge kidney10.9CD40LG, CD79A
18subacute lymphocytic thyroiditis10.9IL2, IL4, TNFSF13B
19esophagus melanoma10.9CD40LG, IL2, IL4
20b cell linker protein deficiency10.9CD40LG, CD79A, TNFRSF13B
21bacteriuria10.9CD40LG, IL2, IL4
22visual snow syndrome10.9IL2, IL4
23variola major10.9CD40LG, CD79A
24mu chain disease10.9CD40LG, CD79A
25brucella abortus brucellosis10.9CD40LG, CD79A, IL2
26loeffler syndrome10.9CD40LG, IL2, IL4
27retinal cancer10.9CD40LG, CD79A
28focal embolic glomerulonephritis10.9CD40LG, CD79A
29lymphoproliferative syndrome, x-linked, 110.9
30lymphoproliferative syndrome, x-linked, 210.9
31impdh1-related leber congenital amaurosis10.9ICOS, NFKB2
32heart disease10.9CD40LG, CD79A
33endometrial stromal nodule10.9CD40LG, CD79A
34aniseikonia10.9CD40LG, CD79A, IL4
35granular cell tumor10.9CD40LG, CD79A, IL4
36diabetic angiopathy10.9CD40LG, CD79A, SH2D1A
37chronic cystitis10.8CD40LG, CD79A
38male urethral cancer10.8CD40LG, CD79A, IL2
39pharyngitis10.8CD79A, IL2, IL4
40van benthem-driessen-hanveld syndrome10.8CD40LG, CD79A
41gait apraxia10.8CD40LG, CD79A, IL4
42early congenital syphilis10.8CD40LG, CD79A, IL2
43malignant histiocytosis10.8CD40LG, CD79A, IL4
44spondylosis10.8CD40LG, CD79A, IL4
45lacrimal system cancer10.8CD40LG, CD79A, IL2
46juvenile dermatitis herpetiformis10.8CD40LG, CD79A, IL4
47lassa fever10.8CD40LG, CD79A, IL2
48bartonellosis10.8CD40LG, CD79A, IL4
49selective iga deficiency disease10.8
50chronic conjunctivitis10.8CD40LG, CD79A, IL4

Graphical network of the top 20 diseases related to Common Variable Immunodeficiency:



Diseases related to common variable immunodeficiency

Symptoms & Phenotypes for Common Variable Immunodeficiency

About this section

Human phenotypes related to Common Variable Immunodeficiency:

 64 54 (show all 33)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sinusitis64 hallmark (90%) HP:0000246
2 otitis media64 54 hallmark (90%) Very frequent (99-80%) HP:0000388
3 thrombocytopenia64 hallmark (90%) HP:0001873
4 lymphopenia64 54 hallmark (90%) Very frequent (99-80%) HP:0001888
5 recurrent respiratory infections64 54 hallmark (90%) Very frequent (99-80%) HP:0002205
6 decreased antibody level in blood64 54 hallmark (90%) Very frequent (99-80%) HP:0004313
7 splenomegaly64 54 typical (50%) Frequent (79-30%) HP:0001744
8 hemolytic anemia64 54 typical (50%) Frequent (79-30%) HP:0001878
9 subcutaneous hemorrhage64 typical (50%) HP:0001933
10 malabsorption64 typical (50%) HP:0002024
11 abnormality of the bronchi64 typical (50%) HP:0002109
12 lymphadenopathy64 54 typical (50%) Frequent (79-30%) HP:0002716
13 elevated hepatic transaminases64 54 typical (50%) Frequent (79-30%) HP:0002910
14 restrictive ventilatory defect64 occasional (7.5%) HP:0002091
15 emphysema64 54 occasional (7.5%) Occasional (29-5%) HP:0002097
16 vasculitis64 54 occasional (7.5%) Occasional (29-5%) HP:0002633
17 lymphoma64 54 occasional (7.5%) Occasional (29-5%) HP:0002665
18 arthralgia64 54 occasional (7.5%) Occasional (29-5%) HP:0002829
19 neoplasm of the stomach64 occasional (7.5%) HP:0006753
20 gastrointestinal stroma tumor64 54 occasional (7.5%) Occasional (29-5%) HP:0100723
21 brachycephaly54 Very frequent (99-80%)
22 chronic otitis media54 Very frequent (99-80%)
23 purpura54 Frequent (79-30%)
24 abnormality of the liver54 Frequent (79-30%)
25 failure to thrive in infancy54 Occasional (29-5%)
26 autoimmune thrombocytopenia54 Very frequent (99-80%)
27 anal atresia54 Frequent (79-30%)
28 pneumonia54 Very frequent (99-80%)
29 restrictive lung disease54 Occasional (29-5%)
30 bronchiectasis54 Frequent (79-30%)
31 immunodeficiency54 Very frequent (99-80%)
32 recurrent bronchitis54 Very frequent (99-80%)
33 posterior pharyngeal cleft54 Occasional (29-5%)

MGI Mouse Phenotypes related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538110.7BTK, CD19, ICOS, IL2, IL4, NFKB1
2MP:000537010.6CD19, IL2, IL4, NFKB1, NFKB2, PRKCD
3MP:00053769.9BTK, CD19, CD40LG, CD79A, CD81, CR2
4MP:00053679.8CD19, CD40LG, CD79A, CR2, IL4, NFKB2
5MP:00053979.5BTK, CD19, CD27, CD40LG, CD79A, CD81
6MP:00053879.5BTK, CD19, CD27, CD40LG, CD79A, CD81

Drugs & Therapeutics for Common Variable Immunodeficiency

About this section

Drugs for Common Variable Immunodeficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 98)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Rivastigmineapproved, investigationalPhase 483123441-03-277991
Synonyms:
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
123441-03-2
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
AB1004572
AC1L2U92
BIDD:GT0316
C11766
CHEMBL636
CID77991
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
D03822
DB00989
ENA 713 free base
 
Ena 713 Free Base
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon
Exelon Patch
HMS2089H18
I06-2037
LS-172571
MolPort-003-666-662
NCGC00167531-01
Rivastigmine (JAN/USAN/INN)
Rivastigmine Hydrogen Tartrate
Rivastigmine [USAN:INN]
Rivastigmine hydrogen tartrate
SDZ 212-713
UNII-PKI06M3IW0
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
rivastigmine
2
Rifaximinapproved, investigationalPhase 410180621-81-46436173
Synonyms:
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-acetate
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV
4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
80621-81-4
88747-56-2
AC-19112
BRN 3584528
Bio-0556
C43H51N3O11
CHEMBL1617
D02554
DB01220
Fatroximin
Flonorm
L 105
L 105 (Ansamacrolide antibiotic)
L 105SV
LS-178059
LS-64147
Lormyx
Lumenax
MLS000759430
Normix
RedActiv
 
Rifacol
Rifamixin
Rifamycin L 105
Rifamycin L 105SV
Rifaxidin
Rifaximin
Rifaximin (USAN/INN)
Rifaximin [USAN:INN]
Rifaximina
Rifaximina [Spanish]
Rifaximine
Rifaximine [French]
Rifaximinum
Rifaximinum [Latin]
Rifaximinun
Rifaxin
Ritacol
S1790_Selleck
SMR000466324
Spiraxin
UNII-L36O5T016N
Xifaxan
Xifaxan, Rifacol, Fatroximin, Rifaximin
Xifaxsan
Xifaxsan (TN)
alpha-0817185
3ImmunoglobulinsPhase 4, Phase 36045
4AntibodiesPhase 4, Phase 36045
5Lithium carbonatePhase 4232554-13-2
6Cholinesterase InhibitorsPhase 4570
7Cholinergic AgentsPhase 43846
8Central Nervous System DepressantsPhase 412806
9Anti-Bacterial AgentsPhase 410884
10Neuroprotective AgentsPhase 41672
11Neurotransmitter AgentsPhase 417734
12Antimanic AgentsPhase 4790
13Tranquilizing AgentsPhase 44164
14Psychotropic DrugsPhase 46279
15Protective AgentsPhase 47190
16rifamycin SVPhase 497
17Gastrointestinal AgentsPhase 48109
18Anti-Infective AgentsPhase 4, Phase 221402
19Antidepressive AgentsPhase 42666
20RifamycinsPhase 497
21Nucleic Acid Synthesis InhibitorsPhase 44855
22Immunoglobulins, IntravenousPhase 4, Phase 3324
23Rho(D) Immune GlobulinPhase 4, Phase 3317
24gamma-GlobulinsPhase 4, Phase 3317
25Immunoglobulin GPhase 4, Phase 3265
26Pharmaceutical SolutionsPhase 3, Phase 27793
27
Pentostatinapproved, investigationalPhase 25353910-25-140926, 439693
Synonyms:
(8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol
(R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol
2'-DCF
2'-Deoxycoformycin
2'-Dexoycoformycin
53910-25-1
59979-24-7
AC1L97UQ
BIDD:GT0136
C02267
CHEBI:41829
CHEMBL1580
CI-825
CID439693
CL-67310465
CO-Vidarabine
Co-V
 
Co-vidarabine
Coforin
Covidarabine
D00155
DB00552
Deoxycoformycin
Nipent
Nipent (TN)
Oncopent
PD-81565
PD-ADI
Pentostatin
Pentostatin (JAN/USAN/INN)
Pentostatina
Pentostatine
Pentostatinum
Vidarbine
Vira A deaminase inhibitor
dCF
pentostatin
28
Sirolimusapproved, investigationalPhase 2189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
29
FludarabineapprovedPhase 2111321679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
30
Mycophenolic acidapprovedPhase 293924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
31
MelphalanapprovedPhase 2712148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
32
alemtuzumabapproved, investigationalPhase 2303216503-57-0
Synonyms:
Campath
 
MabCampath
alemtuzumab
33
Busulfanapproved, investigationalPhase 2, Phase 154055-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
34
Mycophenolate mofetilapproved, investigationalPhase 2939128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
35
ThiotepaapprovedPhase 221652-24-45453
Synonyms:
 
Thioplex
36
Ustekinumabapproved, investigationalPhase 1, Phase 282815610-63-0
Synonyms:
 
Stelera
37
Cyclophosphamideapproved, investigationalPhase 2282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
38
EverolimusapprovedPhase 21896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
39
AzathioprineapprovedPhase 2165446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
40
rituximabapprovedPhase 21654174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
41
Peginterferon alfa-2aapproved, investigationalPhase 2563198153-51-45360545
Synonyms:
198153-51-4
D02747
Pegasys
 
Pegasys (TN)
Peginterferon alfa-2a
Peginterferon alfa-2a (USAN/INN)
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
42Interleukin-12Phase 1, Phase 2130
43VaccinesPhase 26428
44Antirheumatic AgentsPhase 210627
45Antiviral AgentsPhase 29732
46Dermatologic AgentsPhase 1, Phase 25674
47Immunosuppressive AgentsPhase 2, Phase 112770
48AntimetabolitesPhase 211774
49Alkylating AgentsPhase 2, Phase 14694
50Antineoplastic Agents, AlkylatingPhase 2, Phase 14474

Interventional clinical trials:

(show all 44)
idNameStatusNCT IDPhase
1The Rifaximin Study in CVIDCompletedNCT01946906Phase 4
2Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary ImmunodeficiencyCompletedNCT00520494Phase 4
3A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary ImmunodeficiencyCompletedNCT01289847Phase 4
4Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE StudyCompletedNCT01348282Phase 4
5A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®CompletedNCT02247141Phase 3
6Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168012Phase 3
7Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168025Phase 3
8Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00322556Phase 3
9Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement TherapyCompletedNCT00542997Phase 3
10Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency DiseasesCompletedNCT01963143Phase 3
11Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.CompletedNCT00278954Phase 3
12Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsCompletedNCT00220766Phase 3
13A Clinical Study of Intravenous ImmunoglobulinCompletedNCT00468273Phase 3
14Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency DiseasesActive, not recruitingNCT01884311Phase 3
15Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable ImmunodeficiencyRecruitingNCT02199496Phase 1, Phase 2
16Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary ImmunodeficienciesRecruitingNCT02579967Phase 2
17Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency DiseasesRecruitingNCT01852370Phase 1, Phase 2
18Immune Disorder HSCT ProtocolRecruitingNCT01821781Phase 2
19Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed InfantsRecruitingNCT01512888Phase 1, Phase 2
20Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID)Not yet recruitingNCT02789397Phase 2
21Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled TrialNot yet recruitingNCT02661477Phase 2
22"Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable ImmunodeficiencyTerminatedNCT01489618Phase 2
23STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable ImmunodeficiencyCompletedNCT00263237Phase 1
24B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA DeficiencyCompletedNCT00024934Phase 1
25Multivirus-specific Cytotoxic T Lymphocytes (mCTL)RecruitingNCT02510404Phase 1
26Lymphocyte Immunophenotyping in Common Variable ImmunodeficiencyUnknown statusNCT01196702
27Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal SymptomsCompletedNCT00015431
28Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable ImmunodeficiencyCompletedNCT00004695
29Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous ImmunoglobulinCompletedNCT00661401
30Construction of a Health-related Quality of Life (HR-QOL) Questionnaire for Patients With Primary Antibody Deficiency DiseaseCompletedNCT02542228
31Study of Bone Disease in Older HIV-infected AdultsCompletedNCT00935935
32Text Messaging Intervention to Improve HIV Adherence in Rural Drug UsersCompletedNCT01343654
33Immune Regulation in Patients With Common Variable Immunodeficiency and Related SyndromesRecruitingNCT00001244
34Natural History of BronchiectasisRecruitingNCT00943514
35Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation DisordersRecruitingNCT00895271
36Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and OlderRecruitingNCT02960399
37Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesRecruitingNCT01652092
38Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)RecruitingNCT01883921
39My Smart Age With HIV: Smartphone Self-assessment of FrailtyRecruitingNCT02663856
40Investigation of Immune Disorders and DeficienciesActive, not recruitingNCT01981785
41Molecular and Clinical Studies of Primary Immunodeficiency DiseasesEnrolling by invitationNCT00006319
42Improving the Diagnosis of Common Variable Immune DeficiencyNot yet recruitingNCT02680652
43Studies of Disorders in Antibody Production and Related Primary Immunodeficiency StatesTerminatedNCT00266513
44Allogeneic Bone Marrow Transplantation in Patients With Primary ImmunodeficienciesTerminatedNCT00006054

Search NIH Clinical Center for Common Variable Immunodeficiency

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Common Variable Immunodeficiency cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Common Variable Immunodeficiency:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Embryonic/Adult Cultured Cells Related to Common Variable Immunodeficiency:
Umbilical cord blood ALDH+ cells (ALD-151), PMIDs: 10430905


Cochrane evidence based reviews: common variable immunodeficiency

Genetic Tests for Common Variable Immunodeficiency

About this section

Genetic tests related to Common Variable Immunodeficiency:

id Genetic test Affiliating Genes
1 Common Variable Immunodeficiency27
2 Common Variable Immune Deficiency24 TNFRSF13C

Anatomical Context for Common Variable Immunodeficiency

About this section

MalaCards organs/tissues related to Common Variable Immunodeficiency:

36
B cells, Lung, T cells, Spleen, Lymph node, Bone, Bone marrow

Publications for Common Variable Immunodeficiency

About this section

Articles related to Common Variable Immunodeficiency:

(show top 50)    (show all 749)
idTitleAuthorsYear
1
Chitotriosidase enzyme activity: is this a possible chronic inflammation marker in children with common variable immunodeficiency and early atherosclerosis? (27705887)
2017
2
FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). (27896807)
2017
3
Lack of Clinical Hypersensitivity to Penicillin Antibiotics in Common Variable Immunodeficiency. (27873106)
2017
4
Common Variable Immunodeficiency patients with a phenotypic profile of immunosenescence present with thrombocytopenia. (28054583)
2017
5
Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency. (27522107)
2016
6
Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency. (27919819)
2016
7
IL-10-Producing Regulatory B Cells Are Decreased in Patients with Common Variable Immunodeficiency. (26991898)
2016
8
Esophagus-like Bronchus in an Adult with Common Variable Immunodeficiency Disease. (27635435)
2016
9
Impaired CD8(+) T cell responses upon Toll-like receptor activation in common variable immunodeficiency. (27188997)
2016
10
Adult Common Variable Immunodeficiency. (26992251)
2016
11
Impaired selective cytokine production by CD4(+) T cells in Common Variable Immunodeficiency associated with the absence of memory B cells. (27057998)
2016
12
Chronic Giardiasis in a Case of Common Variable Immunodeficiency (CVID): A Case Report. (27630845)
2016
13
Extensive myelitis revealing common variable immunodeficiency. (27374860)
2016
14
Low Circulating Natural Killer Cell Counts are Associated With Severe Disease in Patients With Common Variable Immunodeficiency. (27211564)
2016
15
Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management. (27636680)
2016
16
Spleen Histologic Appearance in Common Variable Immunodeficiency: Analysis of 17 Cases. (27158760)
2016
17
Acute renal dysfunction caused by nonsucrose intravenous immunoglobulin in common variable immunodeficiency. (28024991)
2016
18
Diagnostic criteria for common variable immunodeficiency disorders. (27587325)
2016
19
Anaphylaxis to IGIV in immunoglobulin-naA^ve common variable immunodeficiency patient in the absence of IgG anti-IgA antibodies: successful administration of low IgA-containing immunoglobulin. (27190527)
2016
20
Metachronous Diffuse Large B-Cell Lymphoma and Kaposi Sarcoma of the Right Eyelid and Lacrimal Gland in a Patient with Granulomatous Common Variable Immunodeficiency. (27239466)
2016
21
Accelerated Loss of TCR Repertoire Diversity in Common Variable Immunodeficiency. (27481850)
2016
22
Noninfectious complications in patients with pediatric-onset common variable immunodeficiency correlated with defects in somatic hypermutation but not in class-switch recombination. (27713077)
2016
23
Association between common variable immunodeficiency and collagenous infiltrative disorders of the gastrointestinal tract: A series of four patients. (27053352)
2016
24
Limitation of Simultaneous Analysis of T-Cell Receptor and I_-Deleting Recombination Excision Circles Based on Multiplex Real-Time Polymerase Chain Reaction in Common Variable Immunodeficiency Patients. (27902982)
2016
25
Application of diagnostic and treatment criteria for common variable immunodeficiency disorder. (26623716)
2016
26
Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. (27055021)
2016
27
Evaluation of Known Defective Signaling-Associated Molecules in Patients Who Primarily Diagnosed as Common Variable Immunodeficiency. (26959802)
2016
28
CHARGE Syndrome and Common Variable Immunodeficiency: a case report and review of literature. (27062223)
2016
29
Macronodular Finding of Small Bowel as a Sign of Common Variable Immunodeficiency. (27014747)
2016
30
Disturbed canonical nuclear factor of I_ light chain signaling in BA cells of patients with common variable immunodeficiency. (27461466)
2016
31
Chronic norovirus infection and common variable immunodeficiency. (27753065)
2016
32
Salivary Immunoglobulins in Individuals with Common Variable Immunodeficiency. (27982172)
2016
33
T-Cell Abnormalities in Common Variable Immunodeficiency. (27374799)
2016
34
Myelodysplastic Syndrome and Acute Lymphocytic Leukemia in Common Variable Immunodeficiency (CVID). (26993985)
2016
35
Transient IgG deficiency with lesions in brain and spinal cord: a mimicker of common variable immunodeficiency syndrome. (27848135)
2016
36
T-cell abnormalities in common variable immunodeficiency: the hidden defect. (27153873)
2016
37
Impaired Akt phosphorylation in B-cells of patients with common variable immunodeficiency. (27664934)
2016
38
Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. (26982597)
2016
39
Comparison of various classifications for patients with common variable immunodeficiency (CVID) using measurement of B-cell subsets. (27717724)
2016
40
The B-cell compartment in antibody-deficient infants and young children - developing common variable immunodeficiency or transient immune maturation? (27461226)
2016
41
Assessing Quality of Life in Patients with Common Variable Immunodeficiency: Why It Matters. (27836063)
2016
42
Indications to Epigenetic Dysfunction in the Pathogenesis of Common Variable Immunodeficiency. (27484309)
2016
43
Early and late B-cell developmental impairment in nuclear factor kappa B, subunit 1-mutated common variable immunodeficiency disease. (27555455)
2016
44
Mucosal-associated invariant T cells are depleted and functionally altered in patients with common variable immunodeficiency. (28011187)
2016
45
Important Factors Influencing Severity of Common Variable Immunodeficiency. (27544362)
2016
46
Enhanced formation of giant cells in common variable immunodeficiency: Relation to granulomatous disease. (27856306)
2016
47
Clonal Lymphoproliferations in a Patient With Common Variable Immunodeficiency. (27614471)
2016
48
Common Variable Immunodeficiency and Circulating TFH. (27069935)
2016
49
NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotropic hormone deficiency: A case report and review of literature. (27749582)
2016
50
Resolution of Common Variable Immunodeficiency After HIV Infection. (27763867)
2016

Variations for Common Variable Immunodeficiency

About this section

Expression for genes affiliated with Common Variable Immunodeficiency

About this section
Search GEO for disease gene expression data for Common Variable Immunodeficiency.

Pathways for genes affiliated with Common Variable Immunodeficiency

About this section

Pathways related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

(show all 46)
idSuper pathwaysScoreTop Affiliating Genes
110.3NFKB1, NFKB2
210.2CD19, IL2, MS4A1
310.2IL2, NFKB1, NFKB2
410.2IL2, NFKB1, NFKB2
5
Show member pathways
10.2IL2, NFKB1, NFKB2
610.2IL2, NFKB1, PRKCD
710.2CD27, CD40LG, ICOS
810.2CD40LG, IL4, NFKB1
910.2ICOS, IL2, IL4
1010.2IL2, IL4, NFKB1
1110.2IL2, IL4, NFKB1
12
Show member pathways
10.2IL2, IL4, NFKB1
1310.2CD19, CR2, NFKB1, NFKB2
14
Show member pathways
10.1CD40LG, IL2, IL4
1510.1CD40LG, IL2, IL4
1610.1IL2, NFKB1, NFKB2, TNFRSF13C
1710.1CD19, CR2, IL4, MS4A1
18
Show member pathways
10.1BTK, NFKB1, NFKB2, PRKCD
1910.1CD19, CD40LG, CD81, SH2D1A
20
Show member pathways
10.1IL2, NFKB1, NFKB2, PRKCD
21
Show member pathways
10.1IL2, IL4, NFKB1, NFKB2
22
Show member pathways
10.0CD40LG, ICOS, IL2, NFKB1, PRKCD
23
Show member pathways
10.0CD27, CD40LG, CR2, NFKB1, PRKCD
2410.0CD19, CD79A, IL2, IL4, MS4A1
25
Show member pathways
10.0CR2, NFKB1, NFKB2, TNFRSF13B, TNFRSF13C, TNFSF13B
26
Show member pathways
9.9CD40LG, NFKB1, NFKB2, TNFRSF13B, TNFSF12, TNFSF13B
279.9BTK, CD40LG, NFKB1, NFKB2, TNFRSF13C, TNFSF13B
289.9BTK, CD19, CD40LG, CD79A, ICOS, TNFRSF13B
299.9CD19, CD27, CD40LG, CR2, ICOS, MS4A1
30
Show member pathways
9.9BTK, IL2, IL4, PRKCD, TNFRSF13C, TNFSF13B
319.8BTK, CD40LG, IL2, IL4, TNFSF12, TNFSF13B
32
Show member pathways
9.8CD40LG, IL2, NFKB1, NFKB2, PRKCD, TNFRSF13C
339.8CD40LG, CR2, ICOS, IL4, NFKB1, TNFRSF13B
34
Show member pathways
9.7BTK, CD19, CD79A, CD81, CR2, IL4
35
Show member pathways
9.7CD40LG, ICOS, IL2, IL4, NFKB1, TNFRSF13B
36
Show member pathways
9.7BTK, CD27, CD40LG, PRKCD, TNFRSF13B, TNFRSF13C
37
Show member pathways
9.7BTK, CD40LG, CD79A, ICOS, IL2, IL4
38
Show member pathways
9.6BTK, CD27, CD40LG, NFKB1, PRKCD, TNFRSF13B
39
Show member pathways
9.6BTK, CD19, CD79A, CD81, CR2, IL2
40
Show member pathways
9.5BTK, CD19, CD40LG, CD79A, CD81, CR2
41
Show member pathways
9.4BTK, CD27, CD40LG, IL2, IL4, NFKB1
42
Show member pathways
9.4BTK, CD27, CD40LG, IL2, IL4, NFKB1
43
Show member pathways
9.4BTK, CD27, CD40LG, IL2, IL4, NFKB1
44
Show member pathways
9.4BTK, CD27, CD40LG, IL2, IL4, NFKB1
459.3BTK, CD19, CD40LG, CD79A, ICOS, IL2
46
Show member pathways
9.0BTK, CD19, CD27, CD40LG, CD79A, CD81

GO Terms for genes affiliated with Common Variable Immunodeficiency

About this section

Cellular components related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:000989710.5CD19, CD27, CD40LG, CD79A, ICOS, IL4
2integral component of plasma membraneGO:000588710.5CD19, CD27, CD40LG, CD79A, CD81, ICOS
3plasma membraneGO:00058869.2BTK, CD19, CD27, CD40LG, CD79A, CD81

Biological processes related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

(show all 24)
idNameGO IDScoreTop Affiliating Genes
1immunoglobulin mediated immune responseGO:001606411.0CD27, PRKCD
2immunoglobulin secretionGO:004830511.0CD40LG, TNFSF13B
3negative regulation of cytokine productionGO:000181811.0BTK, NFKB1
4positive regulation of germinal center formationGO:000263611.0TNFRSF13C, TNFSF13B
5I-kappaB kinase/NF-kappaB signalingGO:000724911.0BTK, NFKB1, NFKB2
6B cell receptor signaling pathwayGO:005085310.9BTK, CD19, CD79A
7positive regulation of B cell differentiationGO:004557910.9BTK, CD27
8B cell costimulationGO:003129610.9IL4, TNFRSF13C, TNFSF13B
9cellular defense responseGO:000696810.9CD19, IL4, SH2D1A
10positive regulation of isotype switching to IgG isotypesGO:004830410.9IL2, IL4
11B cell activationGO:004211310.9BTK, CD79A, IL4
12negative regulation of inflammatory responseGO:005072810.9IL2, NFKB1, PRKCD
13B cell differentiationGO:003018310.8CD40LG, CD79A, CR2, IL4
14B cell proliferationGO:004210010.8CD40LG, CD79A, CR2, MS4A1, PRKCD
15positive regulation of NF-kappaB transcription factor activityGO:005109210.8BTK, CD40LG, NFKB1, NFKB2
16innate immune responseGO:004508710.7BTK, CR2, NFKB1, NFKB2, SH2D1A
17adaptive immune responseGO:000225010.7BTK, CD79A, IL2, SH2D1A, TNFRSF13B, TNFRSF13C
18T cell costimulationGO:003129510.7CD40LG, ICOS, TNFRSF13C, TNFSF13B
19positive regulation of B cell proliferationGO:003089010.6CD81, IL2, IL4, TNFRSF13C, TNFSF13B
20negative regulation of apoptotic processGO:004306610.6CD27, CD40LG, IL2, IL4, NFKB1
21positive regulation of T cell proliferationGO:004210210.6CD40LG, IL2, IL4, TNFRSF13C, TNFSF13B
22immune responseGO:000695510.5CD27, CR2, ICOS, IL2, IL4, TNFSF12
23regulation of immune responseGO:005077610.4CD19, CD40LG, CD81, IL4, SH2D1A, TNFRSF13C
24tumor necrosis factor-mediated signaling pathwayGO:00332099.9CD27, CD40LG, TNFRSF13B, TNFRSF13C, TNFSF12, TNFSF13B

Molecular functions related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytokine activityGO:000512510.3CD40LG, IL2, IL4, TNFSF12, TNFSF13B
2tumor necrosis factor receptor bindingGO:000516410.2CD40LG, TNFSF12, TNFSF13B

Sources for Common Variable Immunodeficiency

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet